across for improvements organization. Thank points we to Adding strive the you, ESG, Chirag. always those around
known for are we importantly, to For success for its Amneal. Most push is drive higher. instance, Amneal quality that of system ways our best-in-class the and constantly it people quality looking bar is that
like always, the As local impacting India. organization would associates our team last shared our Thankfully, thank to to service pandemic we make We and the them possible. quarter, of hard we was day our how in improved considerably. situation recognize very call every nearly work has deeply. the On X,XXX healthy who
India loved the team. we has and pandemic by has the saddened on family ones. our tremendous courage and team very demonstrated proud are The we of had Amneal are resiliency toll and However, their our
those of are notably years goals therapeutic updates Now more some much operations, improve supply area and two delivery be product ago, remarkable is focus. These key much later in chain with diversified me improvement our let margins. key as our when provide we mechanisms a offerings our Chirag across returned This we across drug years initiatives. innovation I Two and improved enhance progress key priorities numerous optimize stated agenda. and operations Most Two are considerable continue our years. co-CEOs, profitability. and all seeing areas were multiple global on to to
has and thought strategy over been years. innovation the out deliberate well, our Next
deliver these its dosage Looking categories. form dosage numerous across peers is back, have ability reach forms. from to its We a of differentiated believe in innovations we history innovating drug complex Amneal across
Since are vital R&D competitive Our over driving these for are over capabilities the internally advantages these build we today. us. products. we we and chains innovation developed supply of have these internally manufacturing seeing for the methodically are control And time are that velocity innovations also developed believe better
Going great combinations biosimilars. Today about prioritize complex injectables, our over forward, we we'll feel of pipeline across non-oral to such different inhalation, solid dosage current generics continue as drug implants, XX% Overall, our products products. device is and forms pipeline.
XXXX product such On working which pleased approved we Later with the and ophthalmic Zafemy, this approvals. to expect a are meaningful we as first recently XXXX. new Vasopressin, several is expect We launch of TobraDex, On additional our product. are Copaxone, we Abiraterone in very suspension in half complex expect year, the CRL never half quarter. XXXX. we as diversified large believe have have product Having in very and on a to rely on we the that, respond said with FDA puts that to and first a the path one of approval as we soon us on pipeline. We third launches as
where pipeline with meaningfully than for over doubling XX next see our expand business market. approximately four attractive we have based made on the look million progress Let offerings have $XXX more years our as this institutional We significant in revenues. products we business injectable growth opportunity we Amneal. injectables years the last as for two me and ahead. We the now Today and strategic about commercial annual discuss years in over expect substantial the to view an our rich injectable
of on areas parenteral expertise injectable, as injectable categories developing Our in in large which products portfolio new to products long-acting We look to Each others is entry manufacturing complex certain that team peptides, talented variety look others. internationally Amneal and more by our barriers R&D device requires bags leverage products possess this focused complex Further, near out-licensing we injectable injectable of and for these the such share partnership. space. and at in R&D generics about combinations, a been to volume have approvals term. through we drug
China products to partnership where is in we existing with year. expect Fosun by end Our XX progressing the the well have of about filed
We biosimilars. to pleased filed our accepted Avastin oncology by were have in currently review. biosimilars, BLA on was three June. move that now me under now the We Let for FDA and
products expect start these We commercializing in to XXXX.
evaluating additional to second be or products, Beyond can we via first where are these partnership market. we models first actively opportunities
business beyond, long-term highly in of Looking has and the growth forward new generic of confident bolstered our durability product diversity never and the to launches, been business, by prospects XXXX we the stronger. are
products will a we basis. revenue pipeline. generics. to we pipeline and expect continue. another spending. Going And pace complex annual to point refresh XX in growth constantly have we Currently, to expect generics to XX continue products the durable an XXX trend of long with for see our runway we ANDA to time. our Amneal a of product innovation in on approximately products new innovations will XX generics at XX launches forward, for in ANDAs as approximately any At result, turn in new XXX some file as This the extend we We time, launch expect and and profitability
clinical completed We the pipeline. out to look patient Phase now. are with Phase specialty III in for performing clinical our trial to the coming analysis weeks. III sharing data The forward and our data we trial Turning last the IPXXXX has
carbidopa-levodopa As treatment a next-generation disease. for a Immediate-release therapy is Parkinson's our for treatment first-line reminder, disease. Parkinson's levodopa IPXXXX in is the
Rytary that per day. and frequency would potential versus time in drive Parkinson's that demonstrate than to management data, hopeful leadership Phase has a are will decreasing IR the disease. dosing us We our increased the market the help meaningfully on larger We believe of further III be while product IPXXXX
Beyond in On for, the hypothyroidism; in to IPXXXX, development expect TX we for we lower trihexyphenidyl molecular XXXX. continue the relatively modified the expect for to KXXX, the Myasthenia phase each are for a pivotal and level the programs. modified than of On XXX(b)(X) for a for and programs complete study risk KXXX half we application These to we new PK activities KXXX KXXX study which XXXX. the IND release advance KXXX, clinical is in and second KXXX file all disorders. Sialorrhea currently movement our and Gravis; product are
to release at technologies. in retentive We forward. year a leverage drug platform drug advanced one technology continue that remain oral match timed, from pipeline, can Kashiv we acquisition. specialty the evaluate technology specialty delivery and delivery delivery utilize pulsatile specialty programs our symptoms. per of these product our is utilized gastric is proprietary GRANDE to As going the well build positioned KXXX. provides disease To technology, launch KRONOTEC to the and customized further an unique osmotic drug the timing programs that longer-term KXXX reminder, least
continues Now affordable, all on starting strategy The three DHE the next well creating centered for with In our year company execute businesses: to essential and is summary, stakeholders. value our across medicines Chirag and delivering products the people, and excitement call confidence distribution. auto-injector. patients vision, and generics, at over to distinct now will turn the the in Amneal, ahead. With specialty purpose I this of I, and road Tasos. share for combination
